CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 114 enrolled
Drug / intervention
Levobupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04773301
NCT04773301Phase 4Completed

Randomized and Controlled Phase IV Clinical Trial on the Analgesic Effectiveness of the Combined Blockade in the Hip Fractures of the Elderly: Comparative Study Between Levobupivacaine and Ropivacaine

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León·interventional·Posted Feb 26, 2021·Updated Jul 19, 2024

In Brief

A Phase 4 clinical trial evaluating Levobupivacaine and Ropivacaine for Hip Fractures. Completed, enrolled 114 participants across 1 site.

Detailed Summary

Prospective, low-level, non-commercial intervention, comparative clinical trial (phase IV) of balanced, randomized groups, to compare the analgesic efficacy of the local anesthetics Ropivacaine and Levobupivacaine in peripheral nerve block in hip fracture surgery in the elderly .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Fractures
CountriesSpain

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedFeb 26, 2021
Enrollment StartFeb 13, 2021
Primary CompletionNov 26, 2021
Study CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.4 years ago

Interventions

Levobupivacainedrug

Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine

Ropivacainedrug

Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.